Last reviewed · How we verify
NCT03555630
Thromboelastogram in Postdelivery Preeclamptic Patients
trial testing Thromboelastogram in Preeclampsia in 30 participants. Completed in 31 December 2019.
31 October 2019
Quick facts
| Lead sponsor | Augusta University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 22 May 2018 |
| Primary completion | 31 October 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Thromboelastogram
Conditions studied
- Preeclampsia — all drugs for Preeclampsia →
- Coagulation Disorder — all drugs for Coagulation Disorder →
- Pregnancy Complications — all drugs for Pregnancy Complications →
Sponsor
Augusta University
Who can join
18 and older, female only, with Preeclampsia or Coagulation Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There are no studies evaluating the effect of aging on hemostasis of preeclamptic patients. Additionally, although there are some studies that establish normal reference values for TEG profiles in healthy term pregnant patients, conflicting results have been found in preeclampsia. Reference values are important to establish baseline parameters in cases of pre-eclampsia complicated by postpartum hemorrhage. The investigators will evaluate reference values for TEG in postdelivery preeclamptic patients and the difference between vaginal delivery and cesarean section.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03555630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preeclampsia
Currently open trials in the same condition.
- NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
- NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
- NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
- NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
- NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting
Other Augusta University trials
Trials by the same sponsor.
- NCT07341841 — Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study · NA · enrolling by invitation
- NCT07489144 — CO-creating Novel, Feasible, and Inclusive Research Methods · NA · active not recruiting
- NCT06514014 — Transition From Donor Milk: a Feasibility Study · NA · recruiting
- NCT06907992 — A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated C · not yet recruiting
- NCT06058169 — Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03555630 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Augusta University
- Last refreshed: 24 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03555630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing